Is there a link between very early changes of primary and secondary lymphoid organs in ¹⁸F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?

ABSTRACT: Response assessment or prediction to checkpoint inhibitor therapy (CIT) is an unsolved problem in current routine diagnostics of patients with melanoma. Here, we evaluated very early changes of primary and secondary lymphoid organs under CIT in multiparametric [¹⁸F]-labeled fluorodeoxyglucose-positron emission tomography (¹⁸F-FDG-PET)/MRI as possible predictors of treatment response and investigated their correlation with baseline blood immune biomarkers. Between October 2014 and November 2017, 17 patients with unresectable melanoma (8 females; 65±11 years) undergoing CIT were prospectively evaluated using whole-body ¹⁸F-FDG-PET/MRI before CIT start (t₀), 2 weeks (t₁) and 3 months after CIT initiation (t₂). At each time poin

SUBMITTER: Seith F 

PROVIDER: S-EPMC7406110 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature